The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
The company will provide oncology specimens and associated clinical data to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium.
5AM Solutions will develop software that will allow Asterand to electronically link multiple biorepositories and identify, annotate, and distribute biospecimen data internally and with collaborators.
The contract to supply biospecimens for the Cancer Genome Atlas project could reach a total value of $24 million.
BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.
The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.
BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.
Affymetrix, Febit, Asterand, ImaGenes
BMS will continue to use Asterand's tissue-based drug-discovery products and services for up to three years.
The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.